Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | HPGDS | O60760 | 1/20 | 0.54 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.53 |
| ▸ | HTR2B | P41595 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | EIF4E | P06730 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28216860 | 0.85 | HTR2B (0.69) | ACHEALDH1A1HTR2BMAOAHTR2C | |
| Ammonia Solution, Strong SCHEMBL27976670 | 0.84 | HTR2B (0.68) | ACHEALDH1A1HTR2BMAOAHTR2C | |
| SCHEMBL25414298 | 0.83 | ALDH1A1 (0.59) | ACHEALDH1A1KDM4EHPGDSPTGER1 | |
| SCHEMBL6183496 | 0.83 | ACHE (0.66) | ACHEALDH1A1KDM4EHPGDSPTGER1 | |
| SCHEMBL30634999 | 0.81 | ACHE (0.51) | ACHEALDH1A1KDM4EHTR2BMAOA | |
| SCHEMBL9823334 | 0.81 | HTR2B (0.73) | ACHEALDH1A1KDM4EHPGDSPTGER1 | |
| SCHEMBL2693403 | 0.81 | ACHE (0.63) | ACHEALDH1A1KDM4EHPGDSPTGER1 | |
| SCHEMBL3537686 | 0.81 | ACHE (0.62) | ACHEALDH1A1KDM4EHPGDSPTGER1 | |
| SCHEMBL15754817 | 0.80 | RAB9A (0.60) | ACHEALDH1A1KDM4EMAOA | |
| SCHEMBL2545992 | 0.80 | ACHE (0.61) | ACHEALDH1A1KDM4EHPGDSPTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101370796-A | Thiazoles as 11 beta-HSD1 inhibitors | HOFFMANN LA ROCHE (CH) | 2009-02-18 | — | — | CN | claimed |
| EP-4727546-A2 | PROTEOSOME COMPLEX INHIBITORS TARGETING CLPP1P2 PROTEASE | The Global Alliance for TB Drug Development, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| WO-2025019626-A2 | PROTEOSOME COMPLEX INHIBITORS TARGETING CLPP1P2 PROTEASE | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) | 2025-01-23 | — | — | WO | disclosed |
| US-11834452-B2 | CXCR7 antagonists | CHEMOCENTRYX, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834452-B2 | CXCR7 antagonists | CHEMOCENTRYX, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834452-B2 | CXCR7 antagonists | CHEMOCENTRYX, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| WO-2023170024-A1 | CAMK2 MODULATORS AND THEIR USE IN MEDICINE | UNIVERSITY OF COPENHAGEN (DK) | 2023-09-14 | — | — | WO | disclosed |
| WO-2023170024-A1 | CAMK2 MODULATORS AND THEIR USE IN MEDICINE | UNIVERSITY OF COPENHAGEN (DK) | 2023-09-14 | — | — | WO | disclosed |
| US-20220127272-A1 | CXCR7 ANTAGONISTS | CHEMOCENTRYX, INC. | 2022-04-28 | — | — | US | disclosed |
| US-20220127272-A1 | CXCR7 ANTAGONISTS | CHEMOCENTRYX, INC. | 2022-04-28 | — | — | US | disclosed |
| CN-101730696-A | 3-aza-bicyclo [3.3.0] octane compounds | ACTELION PHARMACEUTICALS LTD | 2010-06-09 | — | — | CN | disclosed |
| CN-101711247-A | 2-cyclopropyl-thiazole derivatives | ACTELION PHARMACEUTICALS LTD | 2010-05-19 | — | — | CN | disclosed |
| US-7645773-B2 | Thiazoles as inhibitors of 11β-hydroxysteroid dehydrogenase | HOFFMANN-LA ROCHE INC. (US) | 2010-01-12 | — | — | US | disclosed |
| CN-101568533-A | 3-heteroaryl (amino or amido)-1- (biphenyl or phenylthiazolyl) carbonylpiperdine derivatives as orexin receptor inhibitors | ACTELION PHARMACEUTICALS LTD (CH) | 2009-10-28 | — | — | CN | disclosed |
| CN-101568536-A | 2-aza-bicyclo[3.1.0]hexane derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2009-10-28 | — | — | CN | disclosed |
| CN-101522618-A | 3-aza-bicyclo[3.1.0]hexane derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2009-09-02 | — | — | CN | disclosed |
| CN-101370796-A | Thiazoles as 11 beta-HSD1 inhibitors | HOFFMANN LA ROCHE (CH) | 2009-02-18 | — | — | CN | disclosed |
| EP-0262873-B1 | N-TETRAZOLYL THIAZOLECARBOXAMIDE DERIVATIVES AND THEIR USE | SAWAI PHARMACEUTICAL CO., LTD. (JP) | 1991-08-21 | — | — | EP | disclosed |
| US-4879295-A | ANTIALLERGENS | SAWAI PHARMACEUTICAL CO., LTD. (JP) | 1989-11-07 | — | — | US | disclosed |
| EP-0262873-A1 | N-tetrazolyl thiazolecarboxamide derivatives and their use | SAWAI PHARMACEUTICAL CO., LTD. (JP) | 1988-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11834452-B2 | CXCR7 antagonists | CXCR1, CXCR5, CCR7 | ACHE 4049/4885ALDH1A1 1699/4885KDM4E 4537/4885 |
| US-20220127272-A1 | CXCR7 ANTAGONISTS | CXCR1, CXCR5, CCR7 | ACHE 4049/4885ALDH1A1 1699/4885KDM4E 4537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.